1
|
Hemminki E, Veerus P, Pisarev H, Hovi SL, Topo P, Karro H. The effects of postmenopausal hormone therapy on social activity, partner relationship, and sexual life - experience from the EPHT trial. BMC WOMENS HEALTH 2009; 9:16. [PMID: 19505307 PMCID: PMC2702282 DOI: 10.1186/1472-6874-9-16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/05/2009] [Accepted: 06/08/2009] [Indexed: 11/10/2022]
Abstract
BACKGROUND With the exception of sexual functioning and weight, social and behavioural effects of postmenopausal hormone therapy (HT) have not been reported from trials. This paper reports such results from the EPHT-trial in Estonia. METHODS A randomized trial, with a blind and non-blind sub-trial in Estonia. From 1999-2001, 1778 women were recruited. The mean follow-up was 3.6 years. Women's experiences were asked in the first and final study year by mailed questionnaires (74 and 81% response rates). Comparisons of the groups were made by cross-tabulation and logistic regression, adjusting for age. RESULTS There were no differences between the HT and non-HT groups in regard to being employed, the extent of social involvement or marital status or opinions on aging. There was no difference in the frequency of free-time exercise, or overweight. Some of the indicators suggested less sexual inactivity, but the differences were small. CONCLUSION In a trial setting, postmenopausal hormone therapy did not influence work or social involvement or health behaviour.
Collapse
Affiliation(s)
- Elina Hemminki
- Health Services and Policy Research, National Institute for Health and Welfare (THL), PO Box 30, Helsinki 00271, Finland.
| | | | | | | | | | | |
Collapse
|
2
|
Hovi SL, Veerus P, Rahu M, Hemminki E. Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial. BMC Med Res Methodol 2008; 8:51. [PMID: 18673555 PMCID: PMC2529341 DOI: 10.1186/1471-2288-8-51] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2007] [Accepted: 08/01/2008] [Indexed: 12/03/2022] Open
Abstract
Background Preventive drugs require long-term trials to show their effectiveness or harms and often a lot of changes occur during post-marketing studies. The purpose of this article is to describe the research process in a long-term randomized controlled trial and discuss the impact and consequences of changes in the research environment. Methods The Estonian Postmenopausal Hormone Therapy trial (EPHT), originally planned to continue for five years, was planned in co-operation with the Women's International Study of Long-Duration Oestrogen after Menopause (WISDOM) in the UK. In addition to health outcomes, EPHT was specifically designed to study the impact of postmenopausal hormone therapy (HT) on health services utilization. Results After EPHT recruited in 1999–2001 the Women's Health Initiative (WHI) in the USA decided to stop the estrogen-progestin trial after a mean of 5.2 years in July 2002 because of increased risk of breast cancer and later in 2004 the estrogen-only trial because HT increased the risk of stroke, decreased the risk of hip fracture, and did not affect coronary heart disease incidence. WISDOM was halted in autumn 2002. These decisions had a major influence on EPHT. Conclusion Changes in Estonian society challenged EPHT to find a balance between the needs of achieving responses to the trial aims with a limited budget and simultaneously maintaining the safety of trial participants. Flexibility was the main key for success. Rapid changes are not limited only to transiting societies but are true also in developed countries and the risk must be included in planning all long-term trials. The role of ethical and data monitoring committees in situations with emerging new data from other studies needs specification. Longer funding for preventive trials and more flexibility in budgeting are mandatory. Who should prove the effectiveness of an (old) drug for a new preventive indication? In preventive drug trials companies may donate drugs but they take a financial risk, especially with licensed drugs. Public funding is crucial to avoid commercial biases. Legislation to share the costs of large post-marketing trials as well as regulation of manufacturer's participation is needed. [ISRCTN35338757]
Collapse
|
3
|
Sievert LL, Saliba M, Reher D, Sahel A, Hoyer D, Deeb M, Obermeyer CM. The medical management of menopause: a four-country comparison care in urban areas. Maturitas 2008; 59:7-21. [PMID: 18178044 DOI: 10.1016/j.maturitas.2007.11.001] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2007] [Revised: 11/19/2007] [Accepted: 11/21/2007] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To compare the medical management of menopause across urban areas in four countries which differ by level of income and degree of medicalization. METHODS Surveys of health providers who advise women on the menopausal transition were carried out in Beirut, Lebanon (n=100), Madrid, Spain (n=60), Worcester, MA, U.S. (n=59), and Rabat, Morocco (n=50) between 2002 and 2004. Physician characteristics, hormone therapy (HT) prescribing practices, and concerns about the management of menopause were compared across countries using chi(2) and logistic regression analyses. RESULTS Across sites, physicians were generally well informed about HT and thought that symptom alleviation and disease prevention were equally important. They had concerns about risks associated with HT, particularly breast cancer, and in 3 sites where the survey was conducted after the WHI (Beirut, Rabat, and Madrid) physicians changed their practices to prescribe HT less frequently, for shorter durations, or shifted to other medications. There were significant differences across sites in the recommended duration of HT, time spent talking with patients, perceived benefits of HT, tests recommended before prescribing HT, and concern about the risks associated with HT. Physicians in Madrid and Massachusetts were more likely to report that decisions about the management of menopause were difficult, but in all sites the main reason for difficulties was concerns about risks. The results also suggest discrepancies between physicians' perceptions and women's reports about the reasons why women consult at menopause. CONCLUSIONS Prescription patterns and perceived benefits of HT appear to reflect local medical culture rather than simply physician characteristics. The impact of the WHI study was seen in prescribing patterns and concerns about HT. Physicians in all four countries were generally well informed. Financial support: NIH 5 900 000196.
Collapse
|
4
|
Maia H, Bossemeyer R, Espinosa-Larrañaga F, Murillo A, Siseles N. Clinical guidelines for improving compliance with hormone therapy in Latin American women during the menopausal transition and thereafter. Maturitas 2006; 56:101-9. [PMID: 16889912 DOI: 10.1016/j.maturitas.2006.06.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2006] [Revised: 05/30/2006] [Accepted: 06/24/2006] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To provide uniform, objective guidance for physicians and other health care workers in Latin America to enhance compliance with hormone therapy (HT), and to provide a tool for continued medical education and a source for answering clinical questions. METHOD Literature search using MEDLINE; identification of key relevant publications by a five-member expert committee; creation and validation of a 60-item questionnaire used to survey the opinion of 72 physicians participating in a Latin American symposium, "The Faces of Menopause". RESULTS On the basis of the validated responses, major points were identified to enhance compliance with HT with specific reference to Latin America, and two algorithms were created to provide practical guidance. CONCLUSION The present guidelines will facilitate optimal compliance with therapy in Latin American postmenopausal women who opt for HT and for whom HT is indicated.
Collapse
Affiliation(s)
- Hugo Maia
- Department of Gynecology, Obstetrics and Human Reproduction, School of Medicine, Federal University of Bahia, Salvador, Bahia, Brazil
| | | | | | | | | |
Collapse
|
5
|
Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas 2006; 55:162-73. [PMID: 16504428 DOI: 10.1016/j.maturitas.2006.01.012] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2005] [Revised: 01/26/2006] [Accepted: 01/30/2006] [Indexed: 11/17/2022]
Abstract
OBJECTIVES At present the Women's Health Initiative trial is the only reported randomised controlled trial studying the effects of hormone therapy among healthy postmenopausal women. The Women's Health Initiative reports have been criticized for lacking in generalisability, due to the characteristics of the trial population. We aimed to compare the health effects of oral continuous combined hormone therapy with a placebo and non-treatment among healthy Estonian women. METHODS Eligible women were randomised into a blind group of hormone therapy versus placebo and into a non-blind group of open label hormone therapy versus non-treatment. One thousand seven hundred and seventy-eight postmenopausal women aged 50-64 at the time of sampling were recruited in 1999-2001 at three clinical centers in Estonia. Participants received conjugated equine oestrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5mg/d, or conjugated equine oestrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 5mg/d, if less than 3 years had passed since menopause at recruitment, or matched placebo or non-treatment. Trial treatment was stopped gradually from 1 January 2004 to 31 May 2004. RESULTS After a follow-up period from 2.0 to 5.0 years the combined hazard ratio, stratified by blinding and adjusted for age at recruitment and former oral contraceptive use was 1.12 (95% confidence interval [CI]: 0.90-1.40) for coronary heart disease, 1.24 (95% CI: 0.85-1.82) for cerebrovascular disease, 1.36 (95% CI: 0.73-2.52) for total cancer, and 0.61 (95% CI: 0.42 to 0.89) for bone fractures. CONCLUSIONS The results from the Estonian Postmenopausal Hormone Therapy randomised trial are consistent with the Women's Health Initiative findings.
Collapse
|
6
|
Legare F, Godin G, Ringa V, Dodin S, Turcot L, Norton J. Variation in the psychosocial determinants of the intention to prescribe hormone therapy prior to the release of the Women's Health Initiative trial: a survey of general practitioners and gynaecologists in France and Quebec. BMC Med Inform Decis Mak 2005; 5:31. [PMID: 16150149 PMCID: PMC1250227 DOI: 10.1186/1472-6947-5-31] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2005] [Accepted: 09/08/2005] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Theory-based approaches are advocated to improve our understanding of prescription behaviour. This study is an application of the theory of planned behaviour (TPB) with additional variables. It was designed to assess which variables were associated with the intention to prescribe hormone therapy (HT). In addition, variations in the measures across medical specialities (GPs and gynaecologists) and across countries (France and Quebec) were investigated. METHODS A survey among 2,000 doctors from France and 1,044 doctors from Quebec was conducted. Data were collected by means of a self-administered questionnaire. A clinical vignette was used to elicit doctors' opinions. The following TPB variables were assessed: attitude, subjective norm, perceived behavioural control, attitudinal beliefs, normative beliefs and power of control beliefs. Additional variables (role belief, moral norm and practice pattern-related factors) were also assessed. A stepwise logistic regression was used to assess which variables were associated with the intention to prescribe HT. GPs and gynaecologists were compared to each other within countries and the two countries were compared within the specialties. RESULTS Overall, 1,085 doctors from France returned their questionnaire and 516 doctors from Quebec (response rate = 54% and 49%, respectively). In the overall regression model, power of control beliefs, moral norm and role belief were significantly associated with intention (all at p < 0.0001). The models by specialty and country were: for GPs in Quebec, power of control beliefs (p < 0.0001), moral norm (p < 0.01) and cytology and hormonal dosage (both at p < 0.05); for GPs in France, power of control beliefs and role belief (both at p < 0.0001) and perception of behavioural control (p < 0.05) and cessation of menses (p < 0.01); for gynaecologists in Quebec, moral norm and power of control beliefs (both at p = 0.01); and for gynaecologists in France, power of control beliefs (p < 0.0001), and moral norm, role belief and lipid profile (all at p < 0.05). CONCLUSION In both countries, compared with GPs, intention to prescribe HT was higher for gynaecologists. Psychosocial determinants of doctors' intention to prescribe HT varied according to the specialty and the country thus, suggesting an influence of contextual factors on these determinants.
Collapse
Affiliation(s)
- France Legare
- CHUQ, St-François d'Assise Hospital Research Center, 10 rue de l'Espinay, Quebec, QC, Canada, G1L 3L5
| | - Gaston Godin
- Canada Research Chair on Behaviour and Health, Faculty of Nursing, Laval University, Quebec, QC, Canada, G1K 7P4
| | - Virginie Ringa
- INSERM National Institute for Medical Research U149, Epidemiological Research Unit on Perinatal Health and Women's Health, 16, ave Paul Vaillant Couturier, 94807 Villejuif cedex, France
| | - Sylvie Dodin
- CHUQ, St-François d'Assise Hospital Research Center, 10 rue de l'Espinay, Quebec, QC, Canada, G1L 3L5
| | - Lucile Turcot
- CHUQ, St-François d'Assise Hospital Research Center, 10 rue de l'Espinay, Quebec, QC, Canada, G1L 3L5
| | - Joanna Norton
- INSERM National Institute for Medical Research U149, Epidemiological Research Unit on Perinatal Health and Women's Health, 16, ave Paul Vaillant Couturier, 94807 Villejuif cedex, France
| |
Collapse
|
7
|
Hovi SL, Veerus P, Karro H, Topo P, Hemminki E. Women's views of the climacteric at the time of low menopausal hormone use, Estonia 1998. Maturitas 2005; 51:413-25. [PMID: 16039416 DOI: 10.1016/j.maturitas.2004.11.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2004] [Revised: 11/04/2004] [Accepted: 11/13/2004] [Indexed: 11/18/2022]
Abstract
OBJECTIVES This study examined women's opinions about the climacteric and hormone therapy (HT) after menopause and compared women's and physicians' opinions in a country of low-HT use. METHODS In 1998, a postal questionnaire was sent to a random sample of 2000 Estonian 45-64-year-old women; 69% (n=1312) responded. In 1999, a postal questionnaire was sent to a random sample of 500 Estonian gynaecologists and general practitioners; 68% (n=342) responded. RESULTS Mean age at menopause was 49.8 years (S.D. 4.0), and there was no difference by socioeconomic classes or by age in self-rated health. Ten percent of women reported having used HT, with 3% currently using it. Most women reported some symptoms, with vasomotor symptoms more frequently reported by 50-54 years old; women most often reported tiredness (48%). Half of the women but under a fifth of physicians considered the climacteric a normal phase of life. Women's awareness about HT was low and about half had no opinion on its health effects. Half of the women had visited a gynaecologist, older women less so. Women with contacts with health care were more aware of HT. CONCLUSIONS Women reported symptoms by age-group as similarly found in high-HT use countries and it verifies that many symptoms experienced were not due to menopause. As in other low-HT use countries, women were unfamiliar with HT and their attitudes were traditional, although physicians' attitudes were more positive. Estonian women seemed to have escaped the period of the preventive use of HT.
Collapse
Affiliation(s)
- Sirpa-Liisa Hovi
- National Research and Development Centre for Welfare and Health, STAKES, Health and Social Services, FI-00530 Helsinki, Finland.
| | | | | | | | | |
Collapse
|
8
|
Hovi SL, Hakama M, Veerus P, Rahu M, Hemminki E. Who wants to join preventive trials?--Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]. BMC Med Res Methodol 2005; 5:12. [PMID: 15826311 PMCID: PMC1090584 DOI: 10.1186/1471-2288-5-12] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2004] [Accepted: 04/12/2005] [Indexed: 11/29/2022] Open
Abstract
Background The interest of patients in participating in randomized clinical trials involving treatments has been widely studied, but there has been much less research on interest in preventive trials. The objective of this study was to find out how many women would be interested in a trial involving postmenopausal hormone therapy (PHT) and how the women's background characteristics and opinions correlated to their interest. Methods The data come from recruitment questionnaires (n = 2000) sent to women in Estonia in 1998. A random sample of women aged 45 to 64 was drawn from the Population Registry. The trial is a two-group randomized trial comparing estrogen-progestogen therapy with placebo or no drugs. A brief description of the study was attached to the questionnaires. Women were not told at this stage of the recruitment which group they would be assigned to, however, they were told of the chance to receive either hormone, placebo or no treatment. Results After two reminders, 1312 women (66%) responded. Eleven percent of the women approached (17% of the respondents) were interested in joining the trial, and 8% wanted more information before deciding. When the 225 women who stated clearly that they were interested in joining and the 553 women who said they were not interested were compared, it was found that interested women were younger and, adjusting for age, that more had given birth; in other respects, the sociodemographic characteristics and health habits of the interested women were similar to those of the non-interested women. The interested women had made more use of more health services, calcium preparations and PHT, they were more often overweight, and more had chronic diseases and reported symptoms. Interested women's opinions on the menopause were more negative, and they favoured PHT more than the non-interested women. Conclusion Unlike the situation described in previous reports on preventive trials, in this case Estonian women interested in participating in a PHT trial were not healthier than other women. This suggests that trials involving PHT are more similar to treatment trials than to preventive trials. In a randomized controlled trial, more information should be obtained from those women who decline to participate.
Collapse
Affiliation(s)
- Sirpa-Liisa Hovi
- National Research and Development Centre for Welfare and Health, STAKES, Health and Social Services, PO Box 220, FI-00531 Helsinki, Finland
- School of Public Health, University of Tampere, FI-33014 Tampere, Finland
| | - Matti Hakama
- School of Public Health, University of Tampere, FI-33014 Tampere, Finland
| | - Piret Veerus
- School of Public Health, University of Tampere, FI-33014 Tampere, Finland
- Department of Epidemiology and Biostatistcs, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia
- Estonian Center of Excellence in Behavioral and Health Sciences, Tartu-Tallinn, Estonia
| | - Mati Rahu
- Department of Epidemiology and Biostatistcs, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia
- Estonian Center of Excellence in Behavioral and Health Sciences, Tartu-Tallinn, Estonia
| | - Elina Hemminki
- National Research and Development Centre for Welfare and Health, STAKES, Health and Social Services, PO Box 220, FI-00531 Helsinki, Finland
| |
Collapse
|
9
|
Hemminki E, Hovi SL, Veerus P, Sevón T, Tuimala R, Rahu M, Hakama M. Blinding decreased recruitment in a prevention trial of postmenopausal hormone therapy. J Clin Epidemiol 2004; 57:1237-43. [PMID: 15617949 DOI: 10.1016/j.jclinepi.2004.04.009] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/20/2004] [Indexed: 10/26/2022]
Abstract
PURPOSE To compare the effect of blind design (active drug and placebo) and nonblind design (active drug and no treatment) on recruitment. SETTING A primary prevention trial with postmenopausal hormone therapy in Estonia. METHODS Women who were eligible and willing to participate on the basis of the questionnaire survey were randomized into blind and nonblind groups. Recruitment rates are based on record keeping, and reasons for participating were requested in the first-year follow-up. RESULTS The recruitment was 30% higher in the nonblind group: of the 4,295 women invited, 37% (95% confidence interval CI=35-39%) in the blind group and 48% (95% CI=46-49%) in the nonblind group were recruited. In both groups, once randomized, most of the losses were women who did not attend the first clinical examination: 49% (blind; 95% CI=47-51%) and 40% (nonblind; 95% CI=38-42%). The rest were found ineligible or lost their interest during clinical examinations. The reasons for joining the trial were relatively similar in the two groups. CONCLUSIONS Blinding decreased women's interest in joining a long-term preventive trial. Women's reasons for joining the trial were not influenced by blinding.
Collapse
Affiliation(s)
- Elina Hemminki
- Health and Social Services, National Research and Development Center for Welfare and Health (STAKES), P.O. Box 220, 00531 Helsinki, Finland.
| | | | | | | | | | | | | |
Collapse
|